Treatment With Lopinavir/Ritonavir or Interferon- beta 1b Improves Outcome of MERS-CoV Infection in...
Treatment With Lopinavir/Ritonavir or Interferon- beta 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
About this item
Full title
Author / Creator
Chan, Jasper Fuk-Woo , Yao, Yanfeng , Yeung, Man-Lung , Deng, Wei , Bao, Linlin , Jia, Lilong , Li, Fengdi , Xiao, Chong , Gao, Hong and Yu, Pin
Journal title
Language
English
Formats
Subjects
More information
Scope and Contents
Contents
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activi...
Alternative Titles
Full title
Treatment With Lopinavir/Ritonavir or Interferon- beta 1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1780500936
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1780500936
Other Identifiers
ISSN
0022-1899
E-ISSN
1537-6613
DOI
10.1093/infdis/jiv392
